Tango Therapeutics Inc Stock

$2.09

4.13% today

Nasdaq, Feb 28, 04:51 pm CET

ISIN

US87583X1090

Symbol

TNGX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Finances

Industry

Financial service provider

Overview Dividends Analysts Charts News Strategies

Tango Therapeutics Inc Stock price

$2.18

-8.05 78.69% 5Y

Nasdaq, Closing price Thu, Feb 27 2025

-0.15 6.44%

ISIN

US87583X1090

Symbol

TNGX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Finances

Industry

Financial service provider

Key metrics

Market capitalization	$234.17m
Enterprise Value	$-21.48m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	0.17
EV/Sales (TTM) EV/Sales	-0.50
P/S ratio (TTM) P/S ratio	5.40
P/B ratio (TTM) P/B ratio	1.02
Revenue growth (TTM) Revenue growth	15.67%
Revenue (TTM) Revenue	$43.38m
EBIT (operating result TTM) EBIT	$-139.70m
Free Cash Flow (TTM) Free Cash Flow	$-123.18m
Cash position	$293.28m
EPS (TTM) EPS	$-1.17
P/E forward	negative
P/S forward	5.44
EV/Sales forward	negative
Short interest	10.19%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

Tango Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Tango Therapeutics Inc forecast:

6x Buy

100%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Tango Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Tango Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	43 43	16% 16% 100%
- Direct Costs	2.50 2.50	50% 50% 6%
Gross Profit	41 41	26% 26% 94%
- Selling and Administrative Expenses	37 37	52% 52% 85%
- Research and Development Expense	141 141	25% 25% 326%
EBITDA	-137 -137	31% 31% -316%
- Depreciation and Amortization	2.50 2.50	50% 50% 6%
EBIT (Operating Income) EBIT	-140 -140	27% 27% -322%
Net Profit	-123 -123	23% 23% -284%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Tango Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

one day ago

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights

– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. Phase 1/2 enrollment expected to begin 1H 2025 – – Clinical collaboration with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio ® (abemaciclib) establis...

Neutral

GlobeNewsWire

●

29 days ago

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotech...

Positive

Seeking Alpha

●

about one month ago

Tango Therapeutics: Chance For A Short Squeeze

Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Given the high short interest and the low number of shares outstanding, I expect a short squeeze to occur, which could lead to an increase in TNGX's share price thereafter. Despite the negative sentiment, recent institutional selling and call option activity suggest potential value accumulatio...

More Tango Therapeutics Inc News

Company Profile

Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Barbara Weber
Employees	140
Founded	2017
Website	www.tangotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now